In this well-designed study, depot olanzapine provided clinically significant prevention of psychotic relapse in outpatients treated with 3 dosing regimes. The highest dose was slightly more effective than the lowest dose but had a greater side effect burden. Injections of 405 mg every 4 weeks, more convenient and possibly safer than injections every 2 weeks, were effective and well tolerated. Because of the risk for postinjection sedation and delirium in approximately 7 injections in 10,000, a 3-hour postinjection observation period is required on the warning label approved by the FDA in December 2009. Given this and the risk for metabolic adverse effects, use of long-acting OP requires careful patient selection.
Recent Research in Antipsychotic Therapy
Комментариев нет:
Отправить комментарий